Regulatory T cells: Customizing for the clinic

Science Translational Medicine

Volumn 3, Issue 83, 2011, Pages

  Wang, Xuehao ^a   Lu, Ling ^a   Jiang, Shuiping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD4 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; DENILEUKIN DIFTITOX; RAPAMYCIN;

ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; EX VIVO STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MELANOMA; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; ARTICLE; DISEASE MODEL; IMMUNOLOGY; MOUSE;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; T-LYMPHOCYTES, REGULATORY;

EID: 79956260076     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001819     Document Type: Review

References (36)

1. regs) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3, 83ra41 (2011).
2. G. Feng, S. N. Nadig, L. Bäckdahl, S. Beck, R. S. Francis, A. Schiopu, A. Whatcott, K. J. Wood, A. Bushell, Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci. Transl. Med. 3, 83ra40 (2011).
3. P. Sagoo, N. Ali, G. Garg, F. O. Nestle, R. I. Lechler, G. Lombardi, Human regulatory T cells with alloantigen specifi city are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 3, 83ra42 (2011).
4. R. K. Gershon, K. Kondo, Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology 18, 723-737 (1970).
5. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
6. K. Wing, S. Sakaguchi, Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11, 7-13 (2010).
7. D. R. Littman, A. Y. Rudensky, Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845-858 (2010).
8. D. J. Campbell, M. A. Koch, Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol. 11, 119-130 (2011).
9. M. Feuerer, J. A. Hill, D. Mathis, C. Benoist, Foxp3+ regulatory T cells: Differentiation, specification, subphenotypes. Nat. Immunol. 10, 689-695 (2009).
10. S. Jiang, Ed., Regulatory T Cells and Clinical Application (Springer, New York, 2008).
11. M. G. Roncarolo, M. Battaglia, Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7, 585-598 (2007).
12. J. D. Fontenot, M. A. Gavin, A. Y. Rudensky, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
13. S. Hori, T. Nomura, S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
14. C. L. Bennett, J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, H. D. Ochs, The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20-21 (2001).
15. E. M. Shevach, Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30, 636-645 (2009).
16. X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martínez-Llordella, M. Ashby, M. Nakayama, W. Rosenthal, J. A. Bluestone, Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000-1007 (2009).
17. D. Q. Tran, H. Ramsey, E. M. Shevach, Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110, 2983-2990 (2007).
18. S. Sakaguchi, M. Miyara, C. M. Costantino, D. A. Hafler, FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
19. M. Miyara, Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z. Amoura, G. Gorochov, S. Sakaguchi, Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899-911 (2009).
20. H17 Cells in Health and Disease (Springer, New York, 2011).
21. J. Wang, T. W. J. Huizinga, R. E. M. Toes, De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. J. Immunol. 183, 4119-4126 (2009).
22. L. Strauss, T. L. Whiteside, A. Knights, C. Bergmann, A. Knuth, A. Zippelius, Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 178, 320-329 (2007).
23. S. Jiang, J. Tsang, D. S. Game, S. Stevenson, G. Lombardi, R. I. Lechler, Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. Transplantation 82, 1738-1743 (2006).
24. G. P. Wright, C. A. Notley, S. A. Xue, G. M. Bendle, A. Holler, T. N. Schumacher, M. R. Ehrenstein, H. J. Stauss, Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Sci. U.S.A. 106, 19078-19083 (2009).
25. J. Y. Tsang, Y. Tanriver, S. Jiang, S. A. Xue, K. Ratnasothy, D. Chen, H. J. Stauss, R. P. Bucy, G. Lombardi, R. Lechler, Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J. Clin. Invest. 118, 3619-3628 (2008).
26. R. Tao, E. F. de Zoeten, E. Ozkaynak, C. Chen, L. Wang, P. M. Porrett, B. Li, L. A. Turka, E. N. Olson, M. I. Greene, A. D. Wells, W. W. Hancock, Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307 (2007).
27. M. Schiff, Abatacept treatment for rheumatoid arthritis. Rheumatology 50, 437-449 (2011).
28. C. P. Larsen, J. Grinyó J. Medina-Pestana, Y. Vanrenterghem, F. Vincenti, B. Breshahan, J. M. Campistol, S. Florman, Mdel. C. Rial, N. Kamar, A. Block, G. Di Russo, C. S. Lin, P. Garg, B. Charpentier, Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 90, 1528-1535 (2010).
29. B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus, R. Hilbrands, E. Vandemeulebroucke, U. Van de Velde, L. Crenier, C. De Block, S. Candon, H. Waldmann, A. G. Ziegler, L. Chatenoud, D. Pipeleers, Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53, 614-623 (2010).
30. T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen, W. Zou, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
31. M. A. Rasku, A. L. Clem, S. Telang, B. Taft, K. Gettings, H. Gragg, D. Cramer, S. C. Lear, K. M. McMasters, D. M. Miller, J. Chesney, Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 6, 12-30 (2008).
32. C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, J. E. Wagner, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117, 1061-1070 (2011).
33. M. Di Ianni, F. Falzetti, A. Carotti, A. Terenzi, F. Castellino, E. Bonifacio, B. Del Papa, T. Zei, R. I. Ostini, D. Cecchini, T. Aloisi, K. Perruccio, L. Ruggeri, C. Balucani, A. Pierini, P. Sportoletti, C. Aristei, B. Falini, Y. Reisner, A. Velardi, F. Aversa, M. F. Martelli, Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921-3928 (2011).
34. P. Trzonkowski, M. Bieniaszewska, J. Juścińska, A. Dobyszuk, A. Krzystyniak, N. Marek, J. Myśliwska, A. Hellmann, First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 133, 22-26 (2009).
35. R. Bacchetta, C. Sartirana, B. Lucarelli, P. Miqueu, M. T. L. Stanghellini, R. Greco, A. Velardi, F. Aversa, M. F Martelli, S. Gregori, E. Zappone, K. Fleischhauer, M. Bernardi, J. Peccatori, F. Ciceri, M. G. Roncarolo, Interleukin-10 anergized donor T cell infusion improves immune reconstitution without severe graft-versus-host-disease after haploidentical hematopoietic stem cell transplantation. Blood 114, ASH meeting abstract #45 (2009).
36. Competing interests: The authors declare no competing interests.